Syneos Health showcased Syneos Health Deployment Solutions at the Future Pharma Conference in Boston. Advancing the traditional outsourced field sales model, Deployment Solutions delivers a customized, integrated mix of promotional and educational channels purposefully designed to ensure successful commercialization.
Eli Lilly and Co.’s LOXO-292, an experimental cancer drug the company acquired in January 2019 as part of an $8 billion takeover of Loxo Oncology, shrank tumors in nearly 70 percent of advanced lung cancer patients whose tumors carried specific abnormalities in the RET gene.
An experimental Amgen Inc. drug that targets a specific genetic mutation reduced tumor size in around half of advanced lung cancer patients given the highest dose in a small, early-stage trial.
Healthline Media partners with wellness advocate Nitika Chopra to create Chronicon, bringing together hundreds of influencers to first daylong event devoted to people struggling with chronic health issues.
Norm Phillips, EVP and Chief Marketing Officer with BioPharm Communications, explains the challenges and opportunities for pharma and describes advantages they have compared to those in the consumer marketing world, such as identifiable influencers, customer-level data and access/reimbursement insights.
Boehringer Ingelheim’s SENSCIS Phase III clinical trial met the primary endpoint for nintedanib in patients with SSc-ILD.
Merck & Co. released data from KEYNOTE-181, a Phase III trial of Keytruda as a monotherapy for the second-line treatment of advanced or metastatic esophageal or esophagogastric junction carcinoma.
Pfizer is ending five preclinical programs in the biosimilar area and cutting 150 positions in Lake Forest, Illinois and in Chennai, India.
The online publication NEO.LIFE pointed to seven areas where biotech companies and researchers have significant potential to “dramatically reshape our concept of what it means to be human.”